Mark is Vice-President of Corporate Development at Denali Therapeutics and leads Alliance Management which is responsible for the industry and academic collaborations that are central to Denali’s corporate strategy. Working closely with Business Development and Portfolio and Program Management, Alliance Management establishes and fosters these strategic relationships to build value for Denali, our partners, our investors, and our patients.

Mark has over 20 years of partnering experience where he has successfully led the sourcing, evaluation, negotiation, and execution of many biopharma collaborations.

Prior to joining Denali in 2019, Mark spent 13 years at Genentech and Roche, most recently as Genentech’s Head of Business Development for Technology Platforms focused on in-licensing drug discovery technology across therapeutic modalities and diseases.

Mark received his B.Sc. in Chemistry from the University of Guelph in Canada.